Search bioRxiv⌕ Search

Biology subjects

Yoon, M. H.

Publications and source records attributed to Yoon, M. H..

2 recordsLinked to original sources

Systematic Analysis of the EXO70 Gene Family in Kiwifruit Species: Evolutionary Selection and Potential Functions in Plant Immunity

BackgroundKiwifruit (Actinidia spp.) is a commercially and nutritionally valuable fruit crop that faces increasing challenges from pathogens, particularly Pseudomonas syringae pv. actinidiae (Psa). The exocyst complex, especially the EXO70 subunit, has been demonstrated to play a crucial role in vesicle trafficking and plant immune responses in model species such as Arabidopsis thaliana. However, the function and evolution of EXO70 genes in fruit crops remain largely unexplored. ResultsWe conducted a comprehensive genome-wide analysis of the EXO70 gene family across five Actinidia species using Arabidopsis EXO70 sequences as queries. A total of 217 EXO70 genes (23 to 54 paralogues per species) were identified and classified into three subfamilies and nine clades (EXO70A-EXO70I), consistent with previous classifications in other plant taxa. Phylogenetic reconstruction and microsynteny analyzes revealed lineage- and genus-specific expansions of EXO70C members, as well as species-specific expansion events, particularly within the EXO70E and EXO70H clades. To investigate potential immune functions, yeast two-hybrid and in planta co-immunoprecipitation assays confirmed that kiwifruit EXO70B1 physically interacts with the immune hub protein kiwifruit RIN4_1. These interactions support conservation of the EXO70-RIN4 module in plant immunity. ConclusionsThis study provides the first comprehensive characterization of the EXO70 gene family across multiple kiwifruit species and uncovers candidate genes potentially involved in plant immunity through RIN4-mediated defense signaling. Notably, the expansion and diversification of the EXO70E and EXO70H clades suggest possible adaptive evolution within these clades and neofunctionalization. These findings provide valuable genomic resources and novel insights into the evolution of vesicle trafficking components in fruit crops, laying the groundwork for future efforts to enhance disease resistance in kiwifruit through breeding or biotechnological approaches.

plant biology↗

Strain diversity drives heterogeneous responses to tuberculosis combination therapy

BackgroundStrain diversity in Mycobacterium tuberculosis (Mtb) underlies distinct clinical presentations and outcomes, but the range of drug susceptibility phenotypes among clinical isolates is poorly understood. We aimed to identify drug response patterns in phylogenetically diverse clinical isolates to combination treatment. MethodsOut of 641 drug-sensitive clinical isolates, we selected 13 strains that capture local and global phylogenetic diversity and included Erdman ATCC-35801 as a reference. We selected ten antibiotics with diverse mechanisms of action to study phenotypic responses to combination therapy. We treated each strain with 10 single drugs, 45 drug pairs, and 20 three-way combinations in standard and cholesterol-rich media. To compare combination treatment responses across strains and conditions that have varying doubling times, we computed normalized growth rate inhibition metrics (GRmax). FindingsMtb clinical strains displayed a broad range of drug response phenotypes across the 65 drug combinations and two metabolic conditions tested. The most effective drug pairs (based on potency and synergy) varied both by strain and metabolic condition. Within our 14-strain panel, strains that were less sensitive to single drugs were also less sensitive to combination treatment, with very few exceptions. For all drug combinations tested, the magnitude of GRmax variation across all strains was driven primarily by variation among genetically related strains, rather than between genetically distant strain groups. InterpretationPreclinical studies should reflect the diversity of Mtb clinical strains; our data suggest that selecting strains based on the range of drug response phenotypes displayed, rather than by genetic diversity alone, may better account for the effects of strain variation. Our findings also support the understanding that constituent drug pairs of high-order combinations target metabolically heterogeneous Mtb. Selection of these pairs should likely involve multiple factors including the infecting strain, metabolic niche, and drug response metrics. FundingGates Foundation INV-027276; NIH P01AI143575&1F32AI174653; Wellcome 206724/Z/17/Z

microbiology↗